Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/564150


Barr: PharmaVitae Generics Profile


Description: Introduction

This analysis examines the historical and forecast performance for Barr in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance. An interactive data and analysis tool provides quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Barrs performance against key rivals in the generic pharmaceutical sector Understand the impact of the Pliva acquisition on Barrs overall performance Evaluate Barrs historical and forecast, branded and generic growth drivers and resistors


Contents: CHAPTER 1 EXECUTIVE SUMMARY 4
Key findings 4
Historical ethical sales performance 5
Therapeutic focus 6
Branded and generic drug outlook, 2006-12 8
Generic drug launch history 8
SWOT analysis 10
Strengths 10
Weaknesses 12
Opportunities 13
Threats 13
CHAPTER 2 CORPORATE HISTORY 18
Key findings 18
Background 19
Key corporate developments 19
M&A history 20
Pliva acquisition 21
M&A strategy 22
Deals and alliances 22
Current corporate structure 24
Current management team 25
CHAPTER 3 HISTORICAL PERFORMANCE 26
Key findings 26
Introduction 27
Revenue and growth rate analysis, 2001-06 27
Revenue and growth rate versus generic peer set 28
Product analysis, 2002-06 30
Growth drivers 30
Growth resistors 31
Operating revenue and cost analysis, 2002-06 32
Operating revenue/cost analysis 33
CHAPTER 4 BRAND FORECAST PERFORMANCE 37
Key findings 37
Overview 38
Branded growth drivers 38
Seasonale 39
ParaGard 39
Cenestin 39
Katadolon 40
2006 launches 40
Branded pipeline 41
CHAPTER 5 KEY PRODUCTS AND COMPETITORS 42
Key findings 42
Overview 43
Therapy area focus, 2002-06 44
Branded portfolio 44
Generic portfolio 45
Generic and biosimilar products 48
Oral contraceptives 48
Warfarin 49
Desmopressin 49
Azithromycin 49
Generic outlook 50
Biosimilar pipeline 53
CHAPTER 6 APPENDIX 54
IMS versus company-reported data reconciliation 54
References 55
Abbreviations 58
Exchange rates 59
List of Tables
Table 1: Barrs product licensing agreements, 2000-06 23
Table 2: Barrs corporate executive committee, 2007 25
Table 3: Generic peer set overview, 2006 29
Table 4: Barrs operating revenue/cost analysis ($m), 2002-06 32
Table 5: Barrs operating cost ratio analysis (% of total revenues), 2002-06 34
Table 6: Barrs branded products with 2006 approval/launch 40
Table 7: Barrs key generic product overview, seven major market sales ($m), 2006 43
Table 8: Generic drugs launched by Barr in the US, fiscal year 2006 50
Table 9: Barrs generic pipeline in the US, 2006 52
Table 10: Exchange rates, 2006 59
List of Figures
Figure 1: Historical ethical (generic and brand) global sales performance for Barr and generic pharma peer set (% CAGR), 2002-06 5
Figure 2: Barrs generic therapeutic focus versus generic pharma peer set (%), 2006 7
Figure 3: Barrs branded and generic drug forecast, 2006-12 8
Figure 4: Percentage revenues attributed to generics launched in the US by Barr and its peer set, 2002-06 9
Figure 5: Barr - SWOT analysis, 2007 10
Figure 6: Barrs M&A history, 2001-06 21
Figure 7: Barrs corporate structure, 2007 24
Figure 8: Barrs global ethical sales revenue and growth rate, ($m), 2001-06 28
Figure 9: Barrs total global ethical revenue and growth rate compared to generic peer set, 2001-06 29
Figure 10: Barrs growth drivers/resistors of historical revenue performance ($m), 2002-06 30
Figure 11: Barr- operating revenue/cost analysis ($ billion), 2002-06 33
Figure 12: Barrs operating cost ratio analysis (% of total revenues), 2002-06 34
Figure 13: Barrs operating cost ratio versus peer set (%), 2006 35
Figure 14: Barrs branded growth drivers, 2006 38
Figure 15: Barrs top seven products, seven major market sales ($m), 2006 44
Figure 16: Barrs branded sales by therapeutic class, 2006 45
Figure 17: Barrs generic sales by therapeutic class, 2006 47
Figure 18: IMS versus company-reported ethical sales discrepancy ($m), 2006 54




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/564150

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 28/11/2009 09:17:36
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Barr: PharmaVitae Generics Profile
Web Address:
http://www.researchandmarkets.com/reports/564150
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €2,613.00 + EUR€ 50.00 Shipping/Handling *
Electronic (PDF) €2,552.00
* Shipping/Handling is only charged once per order.


Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 28/11/2009 09:17:36

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)